[Form 4] CYTOKINETICS INC Insider Trading Activity

Rhea-AI Filing Summary

Kaye Edward M. MD reported acquisition or exercise transactions in this Form 4 filing.

Cytokinetics Inc director Edward M. Kaye, MD received 191 shares of Common Stock as an equity grant. The shares were granted under the Director Equity in Lieu of Cash Retainer Program at a reference price of $65.37 per share and are fully vested. Following this compensation-related award, he directly holds 10,365 shares of Cytokinetics common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kaye Edward M. MD

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	191	$65.37	$12K

Holdings After Transaction: Common Stock — 10,365 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Equity grant size: 191 shares Grant reference price: $65.37 per share Shares owned after grant: 10,365 shares

3 metrics

Equity grant size 191 shares Director equity award on April 15, 2026

Grant reference price $65.37 per share Value used for director stock grant

Shares owned after grant 10,365 shares Director’s direct holdings following award

Key Terms

Director Equity in Lieu of Cash Retainer Program, fully vested, Common Stock

3 terms

Director Equity in Lieu of Cash Retainer Program financial

"Shares of common stock granted pursuant to Director Equity in Lieu of Cash Retainer Program."

fully vested financial

"Shares of common stock granted ... Shares are fully vested."

Common Stock financial

"Shares of common stock granted pursuant to Director Equity in Lieu of Cash Retainer Program."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kaye Edward M. MD

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/15/2026		A(1)		191	A	$65.37	10,365	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of common stock granted pursuant to Director Equity in Lieu of Cash Retainer Program. Shares are fully vested.

	/s/ John Faurescu, attorney-in-fact for Dr. Kaye	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Cytokinetics (CYTK) report for Edward M. Kaye, MD?

Cytokinetics reported that director Edward M. Kaye, MD received 191 shares of Common Stock as an equity grant. The award is part of a director compensation program providing stock instead of cash and represents additional direct ownership in Cytokinetics.

At what price was the Cytokinetics (CYTK) director equity grant recorded?

The 191-share grant to director Edward M. Kaye, MD was recorded at $65.37 per share. This price serves as the reference value for the compensation award, not an open-market purchase or sale price, since the shares were granted as part of a director program.

How many Cytokinetics (CYTK) shares does Edward M. Kaye, MD hold after this grant?

After receiving the 191-share equity grant, Edward M. Kaye, MD directly holds 10,365 shares of Cytokinetics Common Stock. This total reflects his updated direct ownership position reported in the filing following the compensation-related stock award.

Was the Cytokinetics (CYTK) director stock grant fully vested?

Yes, the 191 shares of Common Stock granted to Edward M. Kaye, MD are fully vested. This means the director has complete ownership of the shares immediately, with no additional vesting schedule or service requirements attached to this specific award.

What is the Director Equity in Lieu of Cash Retainer Program at Cytokinetics (CYTK)?

The Director Equity in Lieu of Cash Retainer Program grants directors Cytokinetics Common Stock instead of a cash retainer. In this case, Edward M. Kaye, MD received 191 fully vested shares, reflecting compensation paid in equity rather than cash for board service.